These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 9491911)

  • 1. A human monoclonal antibody specific for the V3 loop of HIV type 1 clade E cross-reacts with other HIV type 1 clades.
    Gorny MK; Mascola JR; Israel ZR; VanCott TC; Williams C; Balfe P; Hioe C; Brodine S; Burda S; Zolla-Pazner S
    AIDS Res Hum Retroviruses; 1998 Feb; 14(3):213-21. PubMed ID: 9491911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cross-clade neutralizing activity of a human monoclonal antibody is determined by the GPGR V3 motif of HIV type 1.
    Zolla-Pazner S; Zhong P; Revesz K; Volsky B; Williams C; Nyambi P; Gorny MK
    AIDS Res Hum Retroviruses; 2004 Nov; 20(11):1254-8. PubMed ID: 15588347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades.
    Gorny MK; Williams C; Volsky B; Revesz K; Cohen S; Polonis VR; Honnen WJ; Kayman SC; Krachmarov C; Pinter A; Zolla-Pazner S
    J Virol; 2002 Sep; 76(18):9035-45. PubMed ID: 12186887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human monoclonal antibodies to the V3 loop of HIV-1 with intra- and interclade cross-reactivity.
    Gorny MK; VanCott TC; Hioe C; Israel ZR; Michael NL; Conley AJ; Williams C; Kessler JA; Chigurupati P; Burda S; Zolla-Pazner S
    J Immunol; 1997 Nov; 159(10):5114-22. PubMed ID: 9366441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B.
    Moore JP; Trkola A; Korber B; Boots LJ; Kessler JA; McCutchan FE; Mascola J; Ho DD; Robinson J; Conley AJ
    J Virol; 1995 Jan; 69(1):122-30. PubMed ID: 7527082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope.
    Gorny MK; Revesz K; Williams C; Volsky B; Louder MK; Anyangwe CA; Krachmarov C; Kayman SC; Pinter A; Nadas A; Nyambi PN; Mascola JR; Zolla-Pazner S
    J Virol; 2004 Mar; 78(5):2394-404. PubMed ID: 14963135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa.
    Bures R; Morris L; Williamson C; Ramjee G; Deers M; Fiscus SA; Abdool-Karim S; Montefiori DC
    J Virol; 2002 Mar; 76(5):2233-44. PubMed ID: 11836401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the neutralization breadth of the anti-V3 antibody F425-B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesis.
    Pantophlet R; Aguilar-Sino RO; Wrin T; Cavacini LA; Burton DR
    Virology; 2007 Aug; 364(2):441-53. PubMed ID: 17418361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of human monoclonal antibodies selected with a hypervariable loop-deleted recombinant HIV-1(IIIB) gp120.
    Jeffs SA; Gorny MK; Williams C; Revesz K; Volsky B; Burda S; Wang XH; Bandres J; Zolla-Pazner S; Holmes H
    Immunol Lett; 2001 Dec; 79(3):209-13. PubMed ID: 11600200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
    Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
    J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV type 1 subtype E-infected patients with broadened, dual (B/E) V3 loop serology have increased cross-neutralizing antibodies.
    Polonis VR; De Souza MS; Chanbancherd P; Chantakulkij S; Jugsudee A; Loomis-Price LD; Vancott TC; Garner R; Markowitz LE; Brown AE; Birx DL
    AIDS Res Hum Retroviruses; 2001 Jan; 17(1):69-79. PubMed ID: 11177385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1.
    Vancott TC; Polonis VR; Loomis LD; Michael NL; Nara PL; Birx DL
    AIDS Res Hum Retroviruses; 1995 Nov; 11(11):1379-91. PubMed ID: 8573396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralizing activity of antibodies to the V3 loop region of HIV-1 gp120 relative to their epitope fine specificity.
    Pantophlet R; Wrin T; Cavacini LA; Robinson JE; Burton DR
    Virology; 2008 Nov; 381(2):251-60. PubMed ID: 18822440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Worldwide distribution of HIV type 1 epitopes recognized by human anti-V3 monoclonal antibodies.
    Cardozo T; Swetnam J; Pinter A; Krachmarov C; Nadas A; Almond D; Zolla-Pazner S
    AIDS Res Hum Retroviruses; 2009 Apr; 25(4):441-50. PubMed ID: 19320565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
    Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
    Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Permissive residues within the minimal epitopes of neutralizing monoclonal antibodies to the V3 loop of HIV-1.
    Laisney IL; Benjamin H; Gefter M; Strosberg AD
    Eur J Immunol; 1996 Jul; 26(7):1634-40. PubMed ID: 8766572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B v3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking.
    Krachmarov C; Pinter A; Honnen WJ; Gorny MK; Nyambi PN; Zolla-Pazner S; Kayman SC
    J Virol; 2005 Jan; 79(2):780-90. PubMed ID: 15613306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A hidden region in the third variable domain of HIV-1 IIIB gp120 identified by a monoclonal antibody.
    Laman JD; Schellekens MM; Lewis GK; Moore JP; Matthews TJ; Langedijk JP; Meloen RH; Boersma WJ; Claassen E
    AIDS Res Hum Retroviruses; 1993 Jul; 9(7):605-12. PubMed ID: 8369165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased Epitope Complexity Correlated with Antibody Affinity Maturation and a Novel Binding Mode Revealed by Structures of Rabbit Antibodies against the Third Variable Loop (V3) of HIV-1 gp120.
    Pan R; Qin Y; Banasik M; Lees W; Shepherd AJ; Cho MW; Kong XP
    J Virol; 2018 Apr; 92(7):. PubMed ID: 29343576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.
    Zwick MB; Kelleher R; Jensen R; Labrijn AF; Wang M; Quinnan GV; Parren PW; Burton DR
    J Virol; 2003 Jun; 77(12):6965-78. PubMed ID: 12768015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.